The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
OBJECTIVE
To evaluate the effects of topical latanoprost, travoprost, and bimatoprost on the blood-aqueous barrier and central corneal thickness (CCT) of patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).


METHODS
Prospective, randomized, masked-observer, crossover clinical trial.


METHODS
A total of 34 phakic patients with POAG or OHT with no previous history of intraocular surgery or uveitis completed the study. Patients were randomized to use latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.03% once daily (2000 hours) for 1 month, followed by a washout period of 4 weeks between each drug. Aqueous flare was measured with a laser flare metre. CCT was calculated as the average of five measurements using ultrasound pachymetry. All measurements were performed by a masked observer (1000 h).


RESULTS
There were no statistically significant differences between baseline mean IOP, mean CCT, and mean flare values among the groups. There was no statistically significant increase in mean flare values from baseline in all groups (P>0.05). There were no statistically significant differences between mean flare values among the groups (P>0.05). All medications significantly reduced the mean IOP from baseline (P<0.0001). IOP reduction obtained with travoprost (7.3+/-3.8 mmHg) was significantly higher than that obtained with latanoprost (4.7+/-4.2 mmHg) (P=0.01). A statistically significant reduction in mean CCT (0.6+/-1.3%) from baseline was observed when patients instilled bimatoprost (P=0.01).


CONCLUSIONS
Latanoprost, travoprost, and bimatoprost had no statistically significant effect on the blood-aqueous barrier of phakic patients with POAG or OHT. Bimatoprost may be associated with a clinically irrelevant reduction in mean CCT.
Arcieri
E S
ES
Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, São Paulo, Brazil. rsaran@triang.com.br
Pierre Filho
P T P
PT
Wakamatsu
T H
TH
Costa
V P
VP
D000328:Adult; D000368:Aged; D000577:Amides / Q000009:adverse effects / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology*; D001082:Aqueous Humor / Q000187:drug effects; D000069580:Bimatoprost; D018916:Blood-Aqueous Barrier / Q000187:drug effects*; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D004812:Epidemiologic Methods; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000494:pharmacology*; D000069557:Travoprost
D000577:Amides; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost